Ioduro (123i) De Sodio Ge Healthcare

Sodium Iodide, the active ingredient in Ioduro (123i) De Sodio Ge Healthcare, is a radioactive diagnostic agent presented as a sterile solution for intravenous use. It is employed in nuclear medicine to image thyroid function and to locate iodine‑avid tissues in patients. GNH USA supplies Ioduro (123i) De Sodio Ge Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ioduro (Sodium Iodide‑123) is used in nuclear medicine procedures that target iodine‑handling tissues. - Thyroid imaging: provides high‑resolution scintigraphy for assessment of thyroid function and morphology. - Detection of ectopic thyroid tissue: helps locate residual or ectopic thyroid tissue after surgery or in congenital cases. - Evaluation of pheochromocytoma: used in specific protocols to image catecholamine‑producing tumors that concentrate iodine.

Common Side Effects: - Nausea: mild, transient discomfort after injection. - Vomiting: occasional, usually self‑limiting. - Headache: mild to moderate, often resolves spontaneously. - Injection site pain: brief discomfort at the venipuncture site. - Transient taste alteration: metallic or iodine taste lasting minutes. - Mild flushing: temporary skin redness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rare but requires immediate medical attention. - Thyrotoxicosis: excessive thyroid hormone release in susceptible individuals. - Radiation‑induced thyroiditis: inflammation of the thyroid gland. - Pulmonary edema: extremely rare, associated with high‑dose exposure. - Severe hypotension: sudden drop in blood pressure post‑administration.

Ioduro (Sodium Iodide‑123) should be used with careful clinical assessment and adherence to radiation safety guidelines. - Pregnancy: avoid unless essential, as fetal thyroid uptake may occur. - Breastfeeding: contraindicated; iodine can be secreted in breast milk. - Thyroid disorders: evaluate baseline thyroid function before administration. - Renal impairment: monitor renal function, as clearance may be reduced. - Allergy to iodine: contraindicated in patients with known hypersensitivity. - Radiation safety: employ appropriate shielding and limit exposure time for staff. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ioduro (Sodium Iodide‑123) may interact with drugs that affect thyroid iodine handling or imaging quality. Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): reduce iodine uptake, compromising image quality. - Lithium therapy: alters thyroid iodine transport, potentially affecting results. - High‑dose iodine supplements: compete for uptake, leading to false‑negative scans. Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may modify baseline activity, requiring dose adjustment of the radiopharmaceutical. - Contrast agents (iodinated): can transiently block iodine uptake; schedule imaging accordingly. - Beta‑blockers: may mask symptoms of adverse reactions such as tachycardia.